Prevention, Early Detection, and Interception最新文献

{"title":"Abstract 647: Immunoprevention of triple negative breast cancer by a TOP2A multi-peptide vaccine","authors":"Sang Beom Lee, Jing Pan, Yueqiang Jiang, Katie A. Palen, Bryon D. Johnson, R. Fernando, S. Sei, R. Lubet, M. You, Yian Wang","doi":"10.1158/1538-7445.SABCS18-647","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-647","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82908256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 4224: SGLT2 is a diagnostic target for early stage lung adenocarcinoma","authors":"B. Villegas, E. Koziolek, Jie Liu, W. Wallace, D. Elashoff, D. Aberle, D. Shackelford, J. Barrio, J. Yanagawa, S. Dubinett, C. Scafoglio","doi":"10.1158/1538-7445.AM2019-4224","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-4224","url":null,"abstract":"Lung cancer is the leading cause of cancer-related death, and lung adenocarcinoma (LUAD) is the most frequent histology. Early diagnosis and treatment are essential; however, there are no targeted diagnostic and therapeutic approaches for early LUAD. An important hallmark of cancer is the increased glucose uptake via GLUT transporters. GLUT activity is imaged in cancer by positron emission tomography (PET) with 2-[18F] fluorodeoxyglucose (FDG). FDG PET is a standard tool for staging advanced lung cancer, but has low sensitivity for early-stage LUAD. This is considered a consequence of slow growth and low requirement of glucose. However, we discovered a novel system of metabolic supply not detected by FDG PET: the sodium glucose transporter 2 (SGLT2)1. SGLT2 activity can be measured in vivo with the PET tracer methyl-4-[18F] fluorodeoxyglucose (Me4FDG). We identified high expression of SGLT2 in human lung premalignancy and early-stage LUAD. Me4FDG detects early-stage, FDG-negative LUAD in mouse models. Targeting SGLT2 with FDA-approved inhibitors significantly reduces tumor growth and prolongs survival in genetic and patient-derived murine models, confirming an important role of SGLT2 in early-stage LUAD2. The reliance of early stage LUAD on SGLT2 opens exciting diagnostic and therapeutic opportunities. The National Lung Screening Trial showed a 20% reduction in lung cancer mortality in high risk individuals using low-dose helical computed tomography (CT). CT is highly sensitive for detecting lung nodules, but is limited by low specificity, especially for LUAD. On CT, LUAD may appear as solid or subsolid nodules. Most subsolid nodules are not cancer, and many will remain stable or resolve; however, subsolid lesions can represent premalignant lesions or adenocarcinoma in situ. These lesions in the early spectrum of LUAD may persist for months to years before transforming into invasive disease. As a result, current standard of care is to follow these patients with CT imaging to monitor these indeterminate lesions for radiologic signs of malignant progression. The identification of novel biomarkers to predict the malignant potential of these nodules at their initial identification is of paramount importance. 1Scafoglio et al. Proc Natl Acad Sci U S A 2015;112(30):E4111-4119 2Scafoglio et al. Sci. Transl. Med. 10, eaat5933 (2018) Citation Format: Brendon Villegas, Eva Koziolek, Jie Liu, W. Dean Wallace, David Elashoff, Denise R. Aberle, David B. Shackelford, Jorge R. Barrio, Jane Yanagawa, Steven M. Dubinett, Claudio Scafoglio. SGLT2 is a diagnostic target for early stage lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4224.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73250977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 667: A mouse model of APOE to define effects of doxorubicin on cognition","authors":"Tamar Demby, Yichien Lee, Olga C. Rodriguez, C. Albanese, J. Mandelblatt, G. Rebeck","doi":"10.1158/1538-7445.SABCS18-667","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-667","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"577 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77203509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 2730: Exceptional activity of ARN-509 (apalutamide) in prostate cancer prevention in rats","authors":"G. Murillo, Xinjian Peng, M. Muzzio, M. Bosland, E. Glaze, C. Suen, D. Mccormick","doi":"10.1158/1538-7445.AM2019-2730","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-2730","url":null,"abstract":"ARN-509 (apalutamide) is a “next-generation” non-steroidal androgen receptor (AR) antagonist that is approved by the FDA for treatment of non-metastatic castration-resistant prostate cancer. Studies were performed in a well-studied rat model to evaluate the efficacy of ARN-509 as an inhibitor of androgen-dependent prostate carcinogenesis. To support dose selection for the prostate cancer chemoprevention bioassay, a six-week pilot study was performed to evaluate the safety of ARN-509 in Wistar rats, and to characterize its PK parameters and dose-response relationships for pharmacodynamic activity (modulation of AR-dependent signaling pathways in the prostate). Several androgen-dependent signaling pathways were modulated by ARN-509; the most reliable biomarker of ARN-509 action in the prostate was down-regulation of kallikrein 1-related peptidase c9 (Klk1c9). Efficacy in prostate cancer prevention was evaluated using a rat model in which invasive prostate cancers are induced by sequential administration of anti-androgen, androgen, and chemical carcinogen (N-methyl-N-nitrosourea; MNU), followed by chronic androgen stimulation. Beginning one week after a single dose of MNU (30 mg/kg), male Wistar rats received daily oral (gavage) administration of ARN-509 at doses of 0 (vehicle control), 15, or 30 mg/kg body weight/day for 60 weeks; a fourth group received daily gavage administration of ARN-509 at 30 mg/kg/day for 60 weeks using an intermittent (one week on; one week off) schedule. Chronic oral administration of ARN-509 was well-tolerated by male Wistar rats; the compound is an extraordinarily potent inhibitor of prostate carcinogenesis. In comparison to a 53% incidence of accessory sex gland cancers (20/38 rats) and a 47% incidence of cancers that were clearly confined to the dorsolateral/anterior prostate (18/38 rats), cancer incidence in the accessory sex glands in both groups of rats receiving continuous daily administration of ARN-509 was 0% (30 mg/kg/day: 0/39 rats; 15 mg/kg/day: 0/37 rats). Intermittent (one week on; one week off) administration of the high dose of ARN-509 (30 mg/kg/day) was also highly effective in cancer prevention, but did not confer the complete protection seen with continuous daily administration: the group receiving intermittent exposure to ARN-509 demonstrated a 10% incidence of accessory sex gland cancer (4/39 rats), with 3% of animals (1/39 rats) demonstrating cancers that were clearly confined to the dorsolateral/anterior prostate. ARN-509 is the most potent inhibitor of prostate carcinogenesis identified in more than two dozen in vivo prostate cancer prevention bioassays performed in our laboratory, and is substantially more active in prostate cancer prevention in this model than is flutamide. These data suggest that ARN-509 merits consideration for evaluation in clinical trials for prostate cancer prevention. [Supported by HHSN261201500042I from NCI] Citation Format: Genoveva Murillo, Xinjian Peng, Miguel Muzzio, M","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75523004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 3331: Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the National Institutes of Health-AARP Diet and Health Cohort Study","authors":"M. Mullooly, D. Withrow, R. Curtis, Shaoqi Fan, L. Liao, R. Pfeiffer, Amy Berrington de González, Gretchen L. Gierach","doi":"10.1158/1538-7445.SABCS18-3331","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-3331","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"96 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74680335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 1613: Dietary isoflavone decreases prostate cancer progression and improves survival in conditionalPten/Trp53-deficient mice","authors":"Yasunori Mori, M. Velasco, Y. Kura, E. Banno, Naomi Ando, N. Sato, M. Nozawa, K. Yoshimura, K. Sakai, K. Yoshikawa, K. Nishio, H. Uemura","doi":"10.1158/1538-7445.AM2019-1613","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1613","url":null,"abstract":"Epidemiological data has shown that dietary practices can greatly influence cancer rates. Men in East Asian countries, men have significantly lower prostate cancer rates compared to their counterparts the US and Europe. Soybeans are a versatile and rich source of protein and its products constitute a rich portion of Asian diets. Recent interest in healthy eating has expanded the consumption of soy products which also provide a rich source of naturally occurring isoflavones and 17β-estradiol. In this study, we used roasted soybean flour (kinako), which contains high levels isoflavones glycosides and estradiol, as dietary soy source to determine the influence of isoflavones rich diets on prostate cancer. Six-week old conditional Pten/Trp53 double knockout mice were randomized and fed plain AIN-93M (Control) diets or a diets supplemented with kinako ad libitum. Concentrations of kinako were adjusted to for daily intakes of aglycone isoflavones (genistein, daidzein, and glycetein) of 400 (LDI) and 800 (HDI) mg. Mice were sacrificed at 16 and 20 weeks (n=6 mice/group) or maintained for survival assessment (n=8 mice/group). Dietary intake of kinako-supplemented diets did not influence the onset of prostatic intraepithelial neoplasia or tumor burden at the early stages. However, tumors from mice fed the HDI diet experienced reduced tumor proliferation rates. Moreover, mice fed LDI and HDI diets showed reduced androgen receptor (AR) protein expression levels as well as mRNA levels for the AR target genes Fkbp5, Nk3x3.1 and Timp4. Interestingly, mice on the LDI diet, but not the HDI, experienced longer times to disease progression (median times 264, 299 and 250 days for Control, LDI and HDI, respectively, P=0.663), tumor doubling (median times 14, 27 and 14 days for Control, LDI and HDI, respectively, P=0.083), cumulative survival (median times 292, 348 and 320 days for Control, LDI and HDI, respectively, P=0.199), and overall survival times (median times 28, 43 and 35 days for Control, LDI and HDI, respectively, P=0.324). The metastatic incidence was 33%, 14% and 14% for Control, LDI and HDI groups, respectively, P=0.631. We also investigated whether dietary intervention with kinako would impact previously stablished tumors. For this we fed kinako supplemented diets to conditional Pten-knockout mice with established tumors but no changes were observed in tumor burden, proliferation, apoptosis and AR activity. Together our data shows that long-term continuous ingestion of a diet rich in isoflavones may be necessary in order suppress tumor growth. Interestingly, this protective effect appears to be lost with high-doses of the dietary isoflavones. Further studies will need to be performed in order to decipher complex dynamic interplay between survival pathways isoflavones chemoprevention. Citation Format: Yasunori Mori, Marco A. De Velasco, Yurie Kura, Eri Banno, Naomi Ando, Noriko Sato, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuko Sakai, Kazuhiro Yoshikawa,","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80337167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 1609: Association between antioxidant levels and inhibition of lung cancer cell proliferation by various garlic extracts","authors":"Z. Farhat, P. Hershberger, D. Aga, T. Scheving, A. Myneni, L. Mu","doi":"10.1158/1538-7445.SABCS18-1609","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1609","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80501816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 4214: A microfluidic platform to capture and detect cancer cells in Leukemia patients","authors":"Rolf Müller, Rachel Toughiri, A. Bartáková, Paul Diaz, C. Carson, P. Armistead, George Fedoriw, M. Foster, M. Zomorrodi, Jennifer Barber-Singh, Veronica Cheung, Emily C Mirkin, R. Melnychuk, Elizabeth Fabio, S. Purushotham, Judy MÛller-Cohn","doi":"10.1158/1538-7445.SABCS18-4214","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4214","url":null,"abstract":"Introduction : BioFluidica has developed a platform, The Liquid Scan™ to analyze circulating cancer cells in whole blood. The Liquid Scan is unique in its performance metrics compared to existing platforms by employing fully automated instrumentation in conjunction with a highly sensitive and a specific cell detection microfluidic chip. This technology can be applied to a broad variety of tumors, including liquid tumors such as leukemias and lymphomas. The unique design of the microfluidic chip permits the capture and analysis of live circulating leukemic cells (CLCs) from whole blood, even when these cells appear undetectable by other methods. The Liquid Scan has been applied to capture CLCs from patients suffering from acute myeloid, as well as acute lymphoblastic leukemia (AML and ALL, respectively). These leukemias are acute diseases of the blood and bone marrow, with mutational changes and clonal expansion of abnormal myeloid and lymphoblastic precursors, respectively claiming a great number of lives every year. Bone marrow biopsies/aspirations have been the standard methods for reliably diagnosis and monitoring these diseases. These procedures are extremely painful for patients, necessitate specialized centers, and trained personnel, which increases the overall cost of treatment. Methods: We have applied the Liquid Scan™ to capture CLCs and characterization, using specific antibodies to capture known clones of leukemic blasts. As a model, we use Kasumi-1, KG-1 and HL-60 cells for AML, and SupB15 cells for ALL, spiked in healthy whole blood. Results: We characterized the ability of the The Liquid Scan™ to capture and release circulating leukemic cells from whole blood, by using cell line models spiked-in whole healthy donor blood and applied to the microfluidic chip. Our results are directly applicable to patient in different stages of the disease, both as an initial diagnostic tool, and as a way to monitor recovery and diagnose relapse. Conclusions: Precision medicine (PM) is significantly changing the treatment of cancer and is bringing new hope for patients. Diagnostic testing for circulating tumor and leukemic cells are promising prognostic and predictive tools for selecting optimal therapies based on the patient’s genetic content. Highly sensitive, and selective BioFluidica’s system is highly sensitive and selective with the capability of rapidly delivering purified and concentrated circulating cancer cells compatible with downstream molecular diagnostics. Citation Format: Rolf Muller, Rachel Toughiri, Alena Bartakova, Paul Diaz, Craig Carson, Paul Armistead, George Fedoriw, Mathew Foster, Maryam Zomorrodi, Jennifer Barber-Singh, Veronica Cheung, Emily Mirkin, Roksolana Melnychuk, Elizabeth Fabio, Sangeetha Purushotham, Judy Muller-Cohn. A microfluidic platform to capture and detect cancer cells in Leukemia patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlant","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83683801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 4220: Evidence of bovine leukemia virus genes detected in Colombian women with and without breast cancer: A zoonotic infection","authors":"N. N. Olaya-Galán, S. P. Salas-Cárdenas, A. P. Corredor-Figueroa, G. Buehring, H. Shen, M. Patarroyo, Fernanda Gutierrez Ma","doi":"10.1158/1538-7445.AM2019-4220","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-4220","url":null,"abstract":"Bovine leukemia virus (BLV), is an oncogenic virus that infects cattle worldwide and is the causative agent of leukemias, lymphomas and persistent lymphocytosis. BLV has also been found in humans and has recently been proposed as a risk factor for developing breast cancer in the USA and Australia. In Colombia, there is evidence of infection in women but no correlation with breast cancer. This study was aimed at comparing the presence of the virus in breast tissue from different sources: necropsies of women without tumor development (normal breast tissue), and surgeries of benign and malignant tumors, to better understand the role of BLV in Colombia. A cross-sectional study was designed in which 315 participants were included. Paired samples of breast tissue and blood were obtained from surgeries and necropsies in Bogota city. The presence of BLV was determined by nested PCR and in situPCR targeting different viral genes. For the nested PCR, DNA was extracted from fresh tissues and blood samples, and human GAPDH amplification was carried out to assess DNA quality for the PCRs. Afterwards, different BLV genes were detected by nested PCR. In situ PCR was directed to the tax region of the virus and was done to FFPE sections of the same samples. Positive samples were considered when at least one of the techniques was positive for the virus and were confirmed by Sanger sequencing. Correlation with other risk factors related with breast cancer (HER2, PR, ER and KI67) and the presence of the virus were determined. From the overall population, 40% of the samples were positive for BLV. In the breast cancer population, 37% of the samples were infected with the virus; similar distributions were found in the other groups (pre-malignant, 33%; benign tumors, 27%). Interestingly, almost 60% of the samples were infected in the no-tumor group. 22% of the samples were positive for both breast tissue and blood from the same patients. All the positive samples were confirmed to have BLV by Sanger sequencing of different gene regions of the virus. When correlating viral presence with other risk factors of breast cancer, it was found that most of the positive BLV samples were also positive for progesterone (79%) and estrogen (93%) receptors and were negative for the HER2 mutation. It could thus be possible that the hormonal profile could be linked with the presence of the virus. This study shows that irrespective of the breast pathology, BLV can be found in Colombian women both in breast tissue and blood. Sanger sequencing showed that the virus found in humans is similar to previously reported sequences obtained from cattle with high identity percentages. Even when the biology of the virus remains unknown in humans, it is a big concern to find the presence of an oncogenic virus coming from animals. Further studies are needed to understand the viral mechanisms related with cancer in humans. Citation Format: Nury N. Olaya-Galan, Sandra P. Salas-Cardenas, Adriana P. Corred","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81604491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 1615: Correlation between demographic factors, dietary habits and urinary micronutrient content among minority groups in New York City","authors":"Cristina N. Zambrano, Maayan Beeber, A. Panitz, K. Wyka, Safa Ibrahim, Yin Tan, G. Ma, K. Navder, Ming-chin Yeh, O. Ogunwobi","doi":"10.1158/1538-7445.SABCS18-1615","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1615","url":null,"abstract":"Cancer is the second leading cause of death in the United States. A diet low in fruits and vegetables increases the risk of certain cancer types. Moreover, socioeconomic factors contribute to limited access to fresh and healthy foods and limited opportunities for safe physical activity, leading to poor physical health. In this multidisciplinary, IRB approved study, we explored relationships between demographic factors, self-reported dietary behaviors and gallic acid, a polyphenolic micronutrient that correlates well with fruit and vegetable intake. We recruited participants at a senior center in East Harlem, New York City, a racially diverse and underserved community. The participants completed a NIH-validated survey through which we assessed their dietary habits and collected standardized demographic data and history of cancer. Urine samples from participants were analyzed for gallic acid. So far, 33 participants completed the survey and 25 of them provided urine samples for gallic acid analysis. We found an association between demographic information (Race/ethnicity and age) and intake of certain foods. Specifically, age was negatively associated with french fries/fried potatoes, cooked dried beans and tomato soup intake (p Citation Format: Cristina Zambrano, Maayan Beeber, April Panitz, Katarzyna Wyka, Safa Ibrahim, Yin Tan, Grace Ma, Khursheed Navder, Ming-Chin Yeh, Olorunseun Ogunwobi. Correlation between demographic factors, dietary habits and urinary micronutrient content among minority groups in New York City [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1615.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84228326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}